Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less

Basit Öğe Kaydı
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authoridUysal, Mukremin/0000-0002-8524-0665
dc.authoridSevinç, Alper/0000-0002-0499-8918
dc.authoridTanriverdi, Ozgur/0000-0002-0598-7284
dc.authoridduran, Ayse Ocak/0000-0002-1703-726X
dc.authoridaksoy, asude/0000-0002-5609-9658
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidYildiz, Yasar/HKN-6909-2023
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.authorwosidSevinc, Alper/KFQ-6440-2024
dc.authorwosidozcelik, melike/AAS-7557-2020
dc.authorwosidUrvay, Semiha/AAM-2335-2021
dc.authorwosidmenekşe, serkan/HNP-3265-2023
dc.contributor.authorOzaslan, Ersin
dc.contributor.authorKaraca, Halit
dc.contributor.authorKoca, Sinan
dc.contributor.authorSevinc, Alper
dc.contributor.authorHacioglu, Bekir
dc.contributor.authorOzkan, Metin
dc.contributor.authorOzcelik, Melike
dc.date.accessioned2024-06-12T10:56:14Z
dc.date.available2024-06-12T10:56:14Z
dc.date.issued2017
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were more effective in neuroendocrine tumors (NETs) with a Ki-67 index of 20% or less. Patients who received SSA or CTx and had unresectable locally advanced and metastatic NETs with a Ki-67 index of 20% or less were retrospectively selected from 13 centers in the Turkish database between 2000 and 2015. One hundred and sixty-five patients were enrolled. The median age was 56 years and the male-to-female ratio was 1.09. Seventy-four (45%) patients were of grade 1 NET and 91 (55%) were of grade 2. SSA was given to 104 patients, whereas 61 were treated with CTx. The objective response rate after SSA was 15.4%; another 73.1% had stable disease. The objective response rate after CTx was 36.1%, and 40.9% had stable disease (P = 0.008). The median PFS in SSA patients was 21 months (95% confidence interval: 12.4-29.6), and 8 months for CTx (95% confidence interval: 5.5-10.6) (P < 0.001). There was no significant difference between PFS of receiving SSA and CTx in pancreatic neuroendocrine tumor (PNET) patients; however, the PFS of receiving SSA was longer in non-PNET patients (P < 0.001). SSA was better treatment in advanced NET patients with a Ki-67 index of less than 5%, having a primary resected and a performance status of 0 (P < 0.05). SSA may be preferred over CTx in advanced NET patients with low-to-intermediate grade. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.en_US
dc.identifier.doi10.1097/CAD.0000000000000445
dc.identifier.endpage229en_US
dc.identifier.issn0959-4973
dc.identifier.issn1473-5741
dc.identifier.issue2en_US
dc.identifier.pmid27768606en_US
dc.identifier.scopus2-s2.0-84992092875en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage222en_US
dc.identifier.urihttps://doi.org/10.1097/CAD.0000000000000445
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19708
dc.identifier.volume28en_US
dc.identifier.wosWOS:000392824000012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofAnti-Cancer Drugsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChemotherapyen_US
dc.subjectKi-67 Indexen_US
dc.subjectLanreotideen_US
dc.subjectNeuroendocrine Tumoren_US
dc.subjectOctreotideen_US
dc.subjectPancreatic Neuroendocrine Tumoren_US
dc.subjectSomatostatin Analogen_US
dc.subjectCarcinoid-Tumorsen_US
dc.subjectGrading Systemen_US
dc.subjectOctreotideen_US
dc.subjectLanreotideen_US
dc.subjectMidguten_US
dc.subjectIndexen_US
dc.titleComparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or lessen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu